
## REDUCE-FMR #TCT2018



**Trial description:** Patients with HF and moderate to severe MR were randomized in a 2:1 fashion to transcatheter mitral annuloplasty with the Carillon device or a sham procedure. Patients were followed for 1 year.



## **RESULTS**

- Primary effectiveness endpoint, change in regurgitant volume at 1 year,
   Carillon vs. sham control: -7.1 vs. 3.3 ml, p = 0.03
- All-cause mortality at 1 year: 12.6% vs. 15.2%
- Change in LV end-diastolic volume at 1 year: -8.6 vs. 6.5 ml, p = 0.06

## **CONCLUSIONS**

 Among patients with HF with dilated LVs and moderate to severe secondary MR, transcatheter mitral annuloplasty with the Carillon device significantly reduced the degree of MR at 1 year compared with sham controls; procedural safety seemed reasonable

Presented by Dr. Horst Sievert at TCT 2018